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Early iron chelation therapy is fundamental in the treatment of β-thalassemia major (β-TM) to avoid the 
adverse effects of chronic transfusional iron overload. Deferiprone (DFP) was the first oral iron 
chelator, but remains second line because of safety concerns.1 Superior efficacy in reducing cardiac 
iron, especially in combination with deferoxamine (DFO), has been shown.2 Its favourable cost-
effectiveness and its off-patent status make it economically interesting both for developed and 
developing countries. Utilization in children is still limited because studies in pediatric patients are 
scarce.  
The independent consortium Deferiprone Evaluation in Paediatrics (DEEP), born within the context of 
the TEDDY Network and funded by the EU Commission, investigates safety and efficacy of DFP. The 
DEEP-3 study investigated the long-term safety of DFP therapy alone and in combination with DFO. 
DEEP-3 was a multi-center, retro- and prospective, non-interventional cohort study which was 
conducted in 16 hospitals in six Mediterranean countries between November 2012 and April 2016: 
Albania (1), Cyprus (1), Egypt (1), Greece (1), Italy (11) and Tunisia (1). Endpoints were the nature 
and incidence of serious and non-serious adverse drug reactions (ADR) to DFP, and potential risk 
factors for ADRs and DFP withdrawals. 
Inclusion criteria were: diagnosis of β-TM and transfusional iron overload, start of DFP at age one 
month to less than 18 years, and at least one dose of DFP. Patients were excluded if previous medical 
records could not be obtained or were incomplete. 
Start of observation was the initiation of DFP therapy. Follow-up ended when the patient either 
completed the study (e.g. turned 18 years of age or end of study) or permanently withdrew from DFP 
for any reason (e.g. adverse reaction). 
The study was approved by all local ethics committees. For prospective data collection, parents or 
guardians provided written, informed consent. 
The investigators were asked to report the following adverse events (AE): hospitalization, fever of 
unknown origin, thrombocytopenia (platelet count <150x109/L), neutropenia (neutrophil count 0.5-
1.5x109/L), agranulocytosis (neutrophil count <0.5x109/L), increased transaminases, arthropathies, 
neurological symptoms, hearing impairments, cardiac symptoms, endocrine dysfunctions, renal 
dysfunctions, weight gain >5% of baseline, gastrointestinal disorders, cutaneous reactions, death, or 
any other clinically important events. 
An independent safety committee evaluated causality, severity and seriousness of each AE. 
Disagreements were solved by consensus. Only AEs deemed at least possibly related to DFP by the 
committee and with positive investigator-reported causality were considered to be an ADR to DFP. 
Additional information on the methods can be found in the Supplementary File. 
Two hundred ninety-seven patients were enrolled and observed from March 1994 to October 2015 
with 717.4 person-years (PY) of follow-up (Table 1). Median patient age at start of DFP therapy was 
8.5 years (range 0.6-17.6 years). One patient died from non-DFP-related vomitus aspiration and 
severe convulsions. Median follow-up per patient was 1.7 years (IQR 0.8-3.5) and ranged from two 
days to 15.2 years. Further details are outlined in Supplementary Table S2.  
Most patients received DFP monotherapy (68.3%). Simultaneous therapy with DFO was predominate 
at Cyprus, Greek and Italian sites (Supplementary Table S3). 
491 AEs including 158 serious AEs in 183 patients underwent the causality assessment (see full list in 
Supplementary Table S4). After assessment, 172 AE episodes in 104 patients were considered to be 
DFP related ADRs (Table 2). The incidence and incidence rate of serious ADRs was 14.8% and 9.5 
per 100 PY, respectively. The probability of experiencing a serious ADR was 20.6% after 36 months of 
treatment (data not shown). ADR incidence did not differ significantly between patients using DFP 
products Ferriprox or Kelfer (P=0.491). 
DFP-related neutropenia was identified in 25 non-splenectomized patients (incidence 8.4%). There 
was no difference in neutropenia incidence between normal spleen size and splenomegaly (P=0.737). 
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In three patients, neutropenia was recurrent despite temporary termination and DFP was eventually 
discontinued.  
Agranulocytosis occurred in two female patients in the first 12 months of treatment without previous 
neutropenia (Figure 1) and recovered upon DFP discontinuation (incidence 0.7%); one patient was on 
combined therapy and one on monotherapy. Both patients received standard DFP and DFO doses 
and had splenomegaly with normal neutrophil levels at baseline. A third case of agranulocytosis was 
demonstrated to be parvovirus B19 related. 
Gastrointestinal disorders, e.g. abdominal pain, diarrhea, dyspepsia, or nausea, were observed with 
incidences ranging between 0.3% and 3.4%. None of these ADRs were serious. Median time to 
occurrence was three months (IQR 0.0-9.0). 
Increased transaminases were seen in 31 patients (incidence 10.4%). The respective alanine 
transaminase levels were as follows: two ADRs <2x upper limit of normal (ULN), 24 ADRs 2-5x ULN, 
14 ADRs 5-10x ULN, and two ADRs >10x ULN. There was no difference between HCV positive and 
negative patients (P=0.549). Median time to first occurrence was eight months (IQR 4-23).  
Arthropathy including arthralgia and swelling, mostly in the knee joints, was the most common ADR 
(Table 2). In five patients therapy was discontinued due to re-occurrence or severe, disabling 
symptoms. More than half of the affected patients experienced symptoms in the first 12 months of 
treatment (Figure 1). North African patients (24.2%) were more often affected than European patients 
(3.8%) (P<0.001). 
Other ADRs identified included mild rash and urticaria, moderate fatigue, mild weight increase, and 
mild chromaturia. No drug-related worsening of hepatic fibrosis, audiological disorders, visual toxicities 
or renal impairments were observed. Adverse reactions disappeared upon temporary DFP 
interruption, dose reduction or even without intervention. 
DFP was discontinued due to AEs (52.9%), lack of efficacy (17.0%) and non-compliance (7.8%). 
Supplementary Tables S5 and S6 provide more details. 
In 23.2% of patients an ADR to DFP led to permanent therapy discontinuation, most commonly due to 
arthropathy, increased transaminases, neutropenia, and gastrointestinal disorders (Table 1). There 
were significantly more ADR-related discontinuations in children under the age of 10 years than in 
older children (P=0.025). No specific risk factors for ADRs or DFP withdrawals could be identified 
(Supplementary Table S7). 
DEEP-3 was the largest safety study of DFP in children so far with more than half of our patients 
below the age of 10 years and more than one-third below six years. 
Compared to adults, neutropenia seems to occur more often in children, even healthy ones.3 
However, our agranulocytosis and neutropenia incidences are similar to those reported in children and 
adolescents on DFP.4 The association between neutropenia and DFP remains uncertain. Our and 
other studies showed that patients recovered despite DFP continuation or did not have neutropenia on 
re-challenge.5-7 Splenectomy may protect from neutropenia as only non-splenectomized patients were 
affected from neutropenia and agranulocytosis. Similar observations have been reported before.1, 8, 9 
Ethnic differences may influence the occurrence of agranulocytosis as reported in Chinese children on 
DFP.10 Combined therapy was not associated with a higher risk for neutropenia consistent with 
existing data.4 European sites reported neutropenia more often than non-European sites (13.5% vs. 
4.3%, P=0.004) due to a closer neutrophil monitoring. 
For agranulocytosis, we can confirm the following observations: it is most likely seen in the first 12 
months of treatment, more often in female patients, and independent from dose and combination with 
DFO.3 The rare occurrence did not allow to investigate potential risk factors. In the literature, it is 
depicted to be idiosyncratic, unpredictable and not dose-dependent.4 
Arthropathy incidence is in agreement with previous studies.4 We could not find a correlation between 
high serum ferritin (SF) and arthropathy, but we found significantly more cases in North African 
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patients. There may be ethnic differences similar to the very high incidences reported in Indian 
children.5, 11, 12 We cannot confirm the influence of different DFP products on the occurrence of 
arthropathy.8, 13  
Elevated transaminases were the second most frequently identified ADR to DFP. We could not find an 
association between the adverse reaction and HCV serostatus or SF levels, respectively. 
Gastrointestinal disorders affected 6.4% of the patients which is lower than reported in previous 
pediatric studies with incidences between 11% and 27.3%.4 The actual incidence may be higher 
because we must take underreporting of mild events into account. 
DFP discontinuation rate was 23.2% in our pediatric cohort. Other observational studies involving real-
world data reported rates of 8.8% and 29.3%.14, 15 ADR-related DFP discontinuations were more 
common in children under the age of 10 years. It may be more difficult to re-administer a drug 
associated with burdensome effects in younger children. 
In conclusion, we did not find any unexpected ADRs and incidences are in accordance with available 
data. Most reactions were mild or moderate and patients recovered shortly upon dose reduction, 
temporary interruption or withdrawal. Neither patients under the age of 6 years, nor under 10 years, 
experienced more ADRs than older patients. We did also not find a greater risk for ADRs in patients 
on combined iron chelation therapy with DFO. 
However, agranulocytosis was also present in this pediatric population. Weekly monitoring of 
neutrophils is warranted. Arthropathy has significant impact on quality of life in children and needs to 
be closely monitored. A new age-appropriate oral formulation of DFP developed in the DEEP project 
may improve gastrointestinal tolerability. Further efforts should be made to facilitate the availability of 
affordable, safe and effective iron chelation for children worldwide. 
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Tables 
 
Table 1: Baseline characteristics 
Patients 297 (100.0) 
Age (years) 8.5 (4.0-12.2) 
 < 6 years 112 (37.7) 
 6-10 years 66 (22.2) 
 > 10 years 119 (40.1) 
 at diagnosis of β-TM 0.8 (0.4-1.2) 
 at start of transfusion therapy 0.7 (0.5-1.2) 
 at start of chelation therapy 2.8 (2.0-4.5) 
Gender 297 (100.0) 
 Female 145 (48.8) 
 Male 152 (51.2) 
Origin 297 (100.0) 
 Europe 131 (44.1) 
 North Africa 154 (51.9) 
 Rest of Africa 1 (0.3) 
 North America 6 (2.0) 
 Latin America 1 (0.3) 
 Asia 4 (1.4) 
β-TM type 84 (100.0) 
 β
0
 / β0 23 (27.4) 
 β
0
 / β+ 28 (33.3) 
 β
+
 / β+ 30 (35.7) 
 Hb Lepore / β0 1 (1.2) 
 Hb Lepore / β+ 1 (1.2) 
 δβ / β+ 1 (1.2) 
Transfusional iron intake 293 (100.0) 
 Low (< 0.3 mg/kg/day) 46 (15.7) 
 Intermediate (0.3-0.5 mg/kg/day) 197 (67.2) 
 High (> 0.5 mg/kg/day) 50 (17.1) 
 Annual blood requirement  
 (mL pure RBC/kg/year) 125 (117-156) 
Spleen status 289 (100.0) 
 Normal 51 (17.7) 
 Splenomegaly 168 (58.1) 
 Splenectomized 70 (24.2) 
Serum ferritin 268 (100.0) 
 < 2,000 ng/mL (n, %) 143 (53.4) 
 2,000-4,000 ng/mL (n, %) 93 (34.7) 
 > 4,000 ng/mL (n, %) 32 (11.9) 
HIV seropositive (n = 183) 0 (0.0) 
Hepatitis B seropositive (n = 237) 10 (4.2) 
Hepatitis C seropositive (n = 242) 41 (16.9) 
Values are median (interquartile range) and number 
of patients, n (%), if not stated otherwise; β-TM: β-
thalassemia major; RBC: red blood cells 
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Table 2: Identified adverse drug reactions (ADR) to deferiprone (DFP) 
MedDRA SOC / 
Preferred Term 
ADRs / 
Patients 
Severity 
mild / 
moderate / 
severe 
Seriousness 
non-serious / 
serious 
Incidence1 
(95% CI) 
Incidence 
rate2 
(95% CI) 
DFP 
discontinuation3 
(95% CI) 
Blood and lymphatic system disorders 
Agranulocytosis 2/2 0/2/0 0/2 0.7 (0.1-2.4) 0.3 (0.0-1.0) 0.7 (0.1-2.4) 
Leukopenia 3/2 3/0/0 3/0 0.7 (0.1-2.4) 0.4 (0.1-1.2) 0.3 (0.0-1.9) 
Neutropenia 38/25 26/12/0 0/38 8.4 (5.5-12.2) 5.3 (3.7-7.3) 5.1 (2.9-8.2) 
Thrombocytopenia 1/1 1/0/0 0/1 0.3 (0.0-1.9) 0.1 (0.0-0.8) 0.3 (0.0-1.9) 
Gastrointestinal disorders 
Abdominal pain 9/8 6/3/0 9/0 2.7 (1.2-5.2) 1.3 (0.6-2.4) 1.0 (0.2-2.9) 
Diarrhea 1/1 1/0/0 1/0 0.3 (0.0-1.9) 0.1 (0.0-0.8) none 
Dyspepsia 4/4 4/0/0 4/0 1.3 (0.4-3.4) 0.6 (0.2-1.4) 0.3 (0.0-1.9) 
Nausea 3/3 1/2/0 3/0 1.0 (0.2-2.9) 0.4 (0.1-1.2) 0.3 (0.0-1.9) 
Salivary 
hypersecretion 1/1 1/0/0 1/0 0.3 (0.0-1.9) 0.1 (0.0-0.8) none 
Vomiting 14/10 3/11/0 14/0 3.4 (1.6-6.1) 2.0 (1.1-3.3) 2.7 (1.2-5.2) 
General disorders and administration site conditions 
Fatigue 1/1 0/1/0 1/0 0.3 (0.0-1.9) 0.1 (0.0-0.8) 0.3 (0.0-1.9) 
Investigations 
Transaminases 
increased 42/31 35/7/0 17/25 10.4 (7.2-14.5) 5.9 (4.2-7.9) 6.4 (3.9-9.8) 
Weight increased 1/1 1/0/0 1/0 0.3 (0.0-1.9) 0.1 (0.0-0.8) none 
Musculoskeletal and connective tissue disorders 
Arthropathy 43/35 10/30/3 41/2 11.8 (8.3-16.0) 6.0 (4.3-8.1) 8.4 (5.5-12.2) 
Bone pain 5/5 2/3/0 5/0 1.7 (0.5-3.9) 0.7 (0.2-1.6) 1.3 (0.4-3.4) 
Renal and urinary disorders 
Chromaturia 1/1 1/0/0 1/0 0.3 (0.0-1.9) 0.1 (0.0-0.8) none 
Skin and subcutaneous tissue disorders 
Rash 2/1 2/0/0 2/0 0.3 (0.0-1.9) 0.3 (0.0-1.0) none 
Urticaria 1/1 0/1/0 1/0 0.3 (0.0-1.9) 0.1 (0.0-0.8) none 
TOTAL 
Any ADR 172/104 97/72/3 104/68 35.0 (29.6-40.7) 24.0 (20.5-27.8) 23.2 (18.6-28.5) 
Any serious ADR 68/44 48/19/1 0/68 14.8 (11.0-19.4) 9.5 (7.4-12.0) 9.1 (6.1-13.0) 
1
 Number of patients with at least one ADR from the corresponding group divided by all exposed patients in 
percent (95% CI); 2 Number of ADR episodes divided by total observation time per 100 PY (95% CI); 3 Number of 
patients permanently discontinuing DFP due to the ADR divided by all exposed patients in percent (95% CI). PY: 
person-years; CI: confidence interval; MedDRA SOC: MedDRA System Organ Class 
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Figure legend 
 
Figure 1: Kaplan-Meier failure analysis 
Values are number of patients at risk at the corresponding time point and in brackets the number of deferiprone-
related adverse drug reactions during the respective 6-month period (only first occurrence considered per 
patient). Censored observation markers and exposure after 60 months have been omitted for the sake of curve 
simplicity. 
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Supplementary Information & Data 
 
Data collection 
Data for this study was collected from medical records at each of the participating sites. This comprised 
demographic data (e.g. gender, year of birth, origin), disease related data (e.g. genotype, age at 
diagnosis, transfusion therapy), medical data (e.g. body weight, Tanner stages, hepatitis B/C or HIV 
status, spleen status), iron chelation details (e.g. actual dose, daily and weekly frequency, reason for 
discontinuation, drug product), laboratory records, co-morbidities, chronic co-medications, and 
occurrence of any adverse event potentially related to DFP therapy. Main laboratory parameters 
included hemoglobin (Hb), white blood count (WBC), neutrophil count (ANC), platelet count (PLT), 
serum creatinine (SCR), alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyl 
transferase (GGT), and serum ferritin (SF). Investigators were instructed to collect and record data on 
a three-monthly basis with the latest available laboratory assessments. All data were recorded, stored 
and handled confidentially in an internet-based and password-protected database with an electronic 
case report form (eCRF). An independent safety committee evaluated causality, severity and 
seriousness of each AE using commonly used assessment tools.1-3 
 
Statistical methods 
The sample size calculation was based on published incidences of agranulocytosis, the most serious 
known ADR to DFP. Based on the expected agranulocytosis incidence from the SPC of 1.1%, it was 
anticipated to observe enough patients to detect at least one case of agranulocytosis with a 95% 
probability.4 The required minimum sample size needed to detect this was 271 patients.5 Including a 
safety margin of 10% (e.g. exclusions due to insufficient data), we planned to enroll at least 298 patients. 
Demographic and baseline characteristics are presented using descriptive statistics. Differences in 
proportions of independent groups were analyzed using Pearson's chi-square test or Fisher's exact test, 
as appropriate. Kruskal-Wallis equality-of-populations rank test was used for comparisons of continuous 
variables of independent groups. 
ADR incidences and incidence rates were calculated by dividing the number of patients with ADR by 
the total number of exposed patients, and by dividing the number of ADRs by the total person-time 
expressed per 100 person-years (PY), respectively. ADR incidences, ADR-related discontinuation rates 
and ADR incidence rates per person-time are presented with 95% confidence intervals (exact binomial 
and Poisson, respectively). For a graphical evaluation of the time-to-occurrence of ADRs and therapy 
discontinuations, Kaplan-Meier failure functions were plotted taking censoring of follow-up into account. 
Logistic regression and Cox proportional hazards methods were used to further explore potential risk 
factors for the dichotomous outcomes ‘occurrence of ADRs (yes, no)’ and ‘withdrawal from DFP 
treatment (yes, no)’, respectively. First, statistically significant predictor variables were identified in 
univariate models using a manual stepwise forward approach. Then, the identified independent 
variables were combined in multivariate models for the dependent outcome variable. If the resulting 
odds ratios (OR) and hazard ratios (HR) were still statistically significant, the predictor was considered 
a potential risk factor for the outcome. The ORs and HRs are reported including 95% confidence interval 
and P-value. We analyzed the following co-variates: gender (female, male), age (≤10 years, >10 years), 
mean DFP dose, chelation regimen (mono, combined), baseline ferritin, HCV serological status (yes, 
no), spleen status (non-splenectomized, splenectomized). Due to the rare incidence of some ADRs, we 
limited this analysis to arthropathy, neutropenia, increased transaminases and gastrointestinal 
disorders. As we expected influences from local practice and center effects, we adjusted all multivariate 
models for country to control for that fact. 
Data processing and statistical analyses were performed using Stata Version 13.1 (StataCorp, College 
Station, Texas, USA). For all statistical tests a type I error (α) of 0.05 was defined and a P-value of <0.05 
was considered statistically significant. 
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Table S1: Definitions applied in the DEEP-3 study 
Term Definition 
Adverse event (AE) Any untoward medical occurrence in a patient or clinical trial subject 
administered a medical product and which does not necessarily have a causal 
relationship with this treatment.6 
Adverse drug reactions (ADR) Response to a medicinal product which is noxious and unintended and which 
occurs at doses normally used in man for the prophylaxis, diagnosis or 
therapy of disease or for the restoration, correction or modification of 
physiological function.7 
Serious adverse event (SAE) An AE was considered serious, if one of the following criteria were met: results 
in death, is life-threatening (at time of occurrence), requires or prolongs 
existing hospitalization, results in disability or incapacity, or results in 
congenital abnormality.8 
Additionally, the following important and severe medical events were always 
considered as serious: acute liver failure, acute renal failure, acute respiratory 
failure, agranulocytosis (neutrophil count less than 0.5x109/L), anaphylaxis, 
any malignancy, aplastic anemia, elevated liver enzymes (alanine 
transaminase (ALT) or aspartate transaminase (AST) more than five times 
baseline values), liver necrosis, malignant hypertension, neutropenia 
(neutrophil count less than 1.5x109/L), pulmonary fibrosis, pulmonary 
hypertension, sclerosing syndromes, seizure (only central neurological 
seizures), thrombocytopenia (platelet count <150x109/L), torsades de pointes, 
toxic epidermal necrolysis, ventricular fibrillation. 
Severity Mild (‘an event that is easily tolerated by the subject, causing minimal 
discomfort and not interfering with everyday activities’);  
Moderate (‘an event that is sufficiently discomforting to interfere with normal 
everyday activities’); 
Severe (‘an event that prevents normal everyday activities’). 
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Table S2: Study characteristics  
 Albania Cyprus Egypt Greece Italy Tunisia 
Study sites 1 1 1 1 11 1 
Start of recruitment Sept 2013 Mar 2015 Apr 2013 Nov 2012 May 2013 Feb 2015 
Enrolled subjects 5 13 154 23 101 14 
 With complete records 5 13 148 23 97 11 
Age (median, range, in years)1 13.3 (10.3-14.4) 
11.1 
(5.0-14.1) 
4.6 
(0.6-17.6) 
10.5 
(3.3-16.9) 
10.5 
(1.1-17.4) 
7.5 
(4.0-12.6) 
Follow-up (total person-years) 13.7 30.8 253.6 73.6 326.2 19.3 
 Retrospective observation 11.3 29.4 230.9 70.3 302.6 19.3 
 Prospective observation 2.4 1.5 22.7 3.4 23.6 0 
 Per patient (median, IQR) 3.3 (1.9-3.5) 1.6 (0.7-3.7) 1.2 (0.7-2.1) 2.7 (1.4-4.8) 2.7 (1.4-4.9) 1.1 (0.3-3.4) 
1 P-value <0.001 
 
 
Table S3: Deferiprone chelation therapy characteristics 
Chelation regimen 297 (100.0) 
 Monotherapy (DFP) 203 (68.3) 
 Combined therapy (DFP/DFO) 59 (19.9) 
 Switched combined regimen 35 (11.8) 
Combined regimen 94 (100.0) 
 Sequential combination 9 (9.6) 
 Simultaneous combination 75 (79.8) 
 Switched combined regimen 10 (10.6) 
Follow-up (years) 717.4 (100.0) 
 On monotherapy (DFP) 497.9 (69.4) 
  Per subject 1.5 (0.8-3.0) 
 On combined therapy (DFP/DFO) 219.4 (30.6) 
  Per subject 1.7 (0.7-3.5) 
DFP product used 297 (100.0) 
 Ferriprox (Apopharma, Canada) 218 (73.4) 
 Kelfer (Cipla, India) 59 (19.9) 
 Multiple products 20 (6.7) 
Chelator dose (mg/kg/day)  
 DFP dose  71.4 (62.5-77.6) 
 DFO dose (in combined therapy) 38.0 (31.2-42.3) 
Co-medications 3 (1-3) 
Co-morbidities 0 (0-1) 
Values are median (IQR) and number of patients, n (%). 
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Table S4: All identified adverse events in DEEP-3 
MedDRA SOC / 
 Preferred Term 
AEs / Patients Severity 
mild / moderate / severe 
Seriousness 
non-serious / serious 
Blood and lymphatic system disorders 
Agranulocytosis 3/3 0/2/1 0/3 
Anemia 1/1 0/0/1 0/1 
Hypersplenism 1/1 1/0/0 1/0 
Leukocytosis 4/3 3/1/0 4/0 
Leukopenia 6/5 5/1/0 6/0 
Lymphadenitis 1/1 1/0/0 1/0 
Neutropenia 55/38 42/13/0 1/54 
Thrombocytopenia 18/18 17/1/0 1/17 
Cardiac disorders 
Cardiac ventricular disorder 1/1 1/0/0 1/0 
Mitral valve incompetence 1/1 1/0/0 1/0 
Palpitations 1/1 1/0/0 1/0 
Endocrine disorders 
Hyperglycemia 3/2 2/1/0 3/0 
Eye disorders 
Visual impairment 1/1 1/0/0 1/0 
Gastrointestinal disorders 
Abdominal distension 1/1 1/0/0 1/0 
Abdominal pain 27/19 15/10/2 26/1 
Diarrhea 10/9 5/5/0 10/0 
Dyspepsia 6/6 5/1/0 6/0 
Dysphagia 1/1 1/0/0 1/0 
Enteritis 3/2 2/1/0 3/0 
Gastrointestinal disorder 1/1 1/0/0 1/0 
Mesenteritis 1/1 0/0/1 0/1 
Nausea 6/5 1/5/0 6/0 
Salivary hypersecretion 1/1 1/0/0 1/0 
Vomiting 23/19 11/12/0 22/1 
General disorders and administration site conditions 
Asthenia 4/3 2/1/1 4/0 
Fatigue 3/3 2/1/0 3/0 
Edema peripheral 1/1 1/0/0 1/0 
Pyrexia 60/35 36/24/0 57/3 
Hepatobiliary disorders 
Hepatocellular injury 1/1 0/1/0 1/0 
Immune system disorders 
Allergic transfusion reaction 4/2 4/0/0 4/0 
Infections and infestations 
Bacterial infection 1/1 0/1/0 1/0 
Bronchitis 1/1 0/1/0 1/0 
Conjunctivitis 1/1 1/0/0 1/0 
Ear infection 1/1 0/1/0 1/0 
Enterobacter bacteremia 1/1 0/0/1 0/1 
Gastroenteritis 2/2 1/1/0 1/1 
Herpes simplex 2/2 2/0/0 2/0 
Measles 1/1 1/0/0 1/0 
Mumps 1/1 1/0/0 1/0 
Otitis externa 1/1 0/1/0 1/0 
Otitis media 3/3 1/2/0 3/0 
Paronychia 1/1 1/0/0 1/0 
Periodontitis 2/1 2/0/0 1/1 
Pharyngitis 6/4 4/2/0 6/0 
Pneumonia 6/4 0/5/1 3/3 
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Table S4: All identified adverse events in DEEP-3 (continued) 
MedDRA SOC / 
Preferred Term 
AEs / Patients Severity 
mild / moderate / severe 
Seriousness 
non-serious / serious 
Infections and infestations 
Respiratory tract infection 6/3 2/4/0 6/0 
Sinusitis 1/1 1/0/0 1/0 
Tinea versicolor 1/1 1/0/0 1/0 
Tonsillitis 6/4 0/6/0 6/0 
Urinary tract infection 1/1 1/0/0 1/0 
Viral infection 3/3 3/0/0 2/1 
Viral upper respiratory tract infection 1/1 1/0/0 1/0 
Injury, poisoning and procedural complications 
Chest injury 1/1 0/1/0 0/1 
Femur fracture 1/1 0/0/1 0/1 
Hemarthrosis 1/1 0/1/0 1/0 
Ligament sprain 1/1 0/1/0 1/0 
Investigations 
Blood creatinine increased 1/1 1/0/0 1/0 
Transaminases increased 84/59 77/7/0 22/62 
Urine calcium increased 4/2 4/0/0 4/0 
Weight increased 1/1 1/0/0 1/0 
Metabolism and nutrition disorders 
Hypocalcaemia 2/2 2/0/0 2/0 
Lactose intolerance 1/1 1/0/0 1/0 
Musculoskeletal and connective tissue disorders 
Arthropathy 56/43 17/36/3 52/4 
Bone pain 6/5 3/3/0 6/0 
Muscle spasms 1/1 1/0/0 1/0 
Osteochondrosis 1/1 0/1/0 0/1 
Pain in extremity 1/1 1/0/0 1/0 
Nervous system disorders 
Dizziness 7/4 6/1/0 7/0 
Headache 3/3 2/1/0 3/0 
Paresthesia 2/2 2/0/0 2/0 
Renal and urinary disorders 
Chromaturia 1/1 1/0/0 1/0 
Nephrolithiasis 1/1 1/0/0 1/0 
Reproductive system and breast disorders 
Amenorrhea 2/1 2/0/0 2/0 
Menstrual disorder 1/1 1/0/0 1/0 
Respiratory, thoracic and mediastinal disorders 
Aspiration 1/1 0/0/1 0/1 
Cough 1/1 1/0/0 1/0 
Skin and subcutaneous tissue disorders 
Dermatitis bullous 1/1 1/0/0 1/0 
Erythema 1/1 1/0/0 1/0 
Eyelid edema 1/1 1/0/0 1/0 
Pruritus 1/1 1/0/0 1/0 
Rash 5/4 3/2/0 5/0 
Skin irritation 1/1 1/0/0 1/0 
Skin ulcer 1/1 1/0/0 1/0 
Urticaria 1/1 0/1/0 1/0 
TOTAL 491/183 319/159/13 333/158 
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Table S5: Reasons for DFP discontinuation based on therapy duration 
 Duration of DFP treatment 
Reasons for 
discontinuation 
< 1 year  
62 (100.0) 
1-3 years  
55 (100.0) 
> 3 years  
36 (100.0) 
Total  
153 (100.0) 
Adverse event 43 (69.4) 27 (49.1) 11 (30.6) 81 (52.9) 
Lack of efficacy 2 (3.2) 11 (20.0) 13 (36.1) 26 (17.0) 
Other1 8 (12.9) 10 (18.2) 4 (11.1) 22 (14.5) 
Non-compliance 5 (8.1) 2 (3.6) 5 (13.9) 12 (7.8) 
SF normalized 2 (3.2) 4 (7.3) 2 (5.7) 8 (5.2) 
Safety concerns 2 (3.2) 1 (1.8) 1 (5.6) 4 (2.6) 
Values are number of patients, n (%); 1 Patient preference for DFX (n=11), DFP not available (n=4), 
participation in a clinical trial (n=4), reimbursement ceased (n=3); SF: serum ferritin. 
 
 
Table S6: Adverse events resulting in DFP therapy discontinuation 
Adverse events n 
(%) 
DFP related 
yes/no 
 Arthropathy 26 (8.8) 25/1 
 Transaminases increased 21 (6.7) 19/2 
 Neutropenia 18 (6.1) 15/3 
 Gastrointestinal disorders 9 (3.0) 9/0 
 Thrombocytopenia 4 (1.3) 1/3 
 Agranulocytosis 3 (1.0) 2/1 
 Leukopenia 3 (1.0) 1/2 
 Bone pain 2 (0.7) 2/0 
 Palpitations 1 (0.3) 0/1 
 Enterobacter bacteremia 1 (0.3) 0/1 
 Fatigue 1 (0.3) 1/0 
 Worsened hepatocellular injury 1 (0.3) 0/1 
 Vomitus aspiration (fatal) 1 (0.3) 0/1 
Values are number of patients affected (n) and incidence (%) in the total 
cohort (n=297). AEs add up to more than 81 patients, because in 8 patients 
a combination of AEs led to discontinuation. 
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Table S7: Potential risk factors for ADR occurrence or DFP therapy discontinuation 
 Univariate regression Multivariate regression 
ADR / Risk factor OR (95% CI)1 P-value OR (95% CI)1 P-value 
Arthropathy     
 Regimen (mono vs. combined therapy) 10.5 (1.4-78.3) 0.022 4.8 (0.6-39.0) 0.139 
 Splenectomized vs. non-splenectomized 2.4 (1.2-5.1) 0.019 2.4 (1.0-5.9) 0.051 
 Age (≤10 years vs. >10 years) 2.5 (1.1-5.7) 0.031 2.6 (0.9-7.6) 0.084 
 Mean DFP dose 1.0 (0.9-1.0) 0.041 1.0 (0.9-1.0) 0.161 
Neutropenia     
 Regimen (combined vs. monotherapy) 2.9 (1.1-7.2) 0.025 1.7 (0.5-5.4) 0.370 
Transaminases increased     
 - - - - - 
Gastrointestinal disorders     
 - - - - - 
Discontinuation / Risk factor HR (95% CI)2 P-value HR (95% CI)2 P-value 
DFP discontinuation     
 Age (≤10 years vs. >10 years) 1.6 (1.1-2.2) 0.009 1.1 (0.7-1.7) 0.636 
 Regimen (mono vs. combined therapy) 1.6 (1.0-2.4) 0.039 1.2 (0.7-2.1) 0.418 
 Mean DFP dose 1.0 (0.9-1.0) 0.041 1.0 (0.9-1.0) 0.496 
1 Logistic regression model odds ratio and confidence interval for the dependent variable ADR occurrence.  
2 Cox regression model odds ratio and confidence interval adjusted for the time-dependent variable DFP 
discontinuation. All multivariate models adjusted for country. 
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